Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy
2007

Docetaxel Dosing in Lung Cancer Treatment

Sample size: 34 publication Evidence: moderate

Author Information

Author(s): Fr Brunsvig Paal, Andersen Anders, Aamdal Steinar, Kristensen Vessela, Olsen Harald

Primary Institution: Rikshospitalet-Radiumhospitalet Medical Centre

Hypothesis

The pharmacokinetics and radiosensitizing efficacy of weekly 20 mg/m2 docetaxel has not been well characterized compared to a 3-weekly 100 mg/m2 regimen.

Conclusion

Weekly docetaxel at 20 mg/m2 can maintain plasma concentrations that may support its use as a radiosensitizer for up to a week.

Supporting Evidence

  • The study demonstrated that docetaxel plasma levels can be maintained above 1 nM for 72 hours after administration.
  • Median docetaxel plasma levels of 3 nM were observed 72 hours after a dose of 20 mg/m2.
  • The pharmacokinetics of docetaxel showed significant inter-individual variability.

Takeaway

This study looked at how a lower dose of docetaxel can still be effective in treating lung cancer when given weekly, especially when combined with radiation.

Methodology

The study involved 34 patients with NSCLC, comparing pharmacokinetics of 20 mg/m2 weekly docetaxel with 100 mg/m2 every 3 weeks.

Limitations

The study had a small sample size and was descriptive in nature without planned statistical comparisons.

Participant Demographics

{"total_patients":34,"male":18,"female":16,"median_age":63,"age_range":"45-81"}

Digital Object Identifier (DOI)

10.1186/1471-2407-7-197

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication